{"id":"hydroxypropyl-beta-cyclodextrin","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4303326","moleculeType":"Small molecule","molecularWeight":"1541.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclodextrins are cyclic oligosaccharides with a hydrophobic cavity that can encapsulate poorly water-soluble compounds, increasing their solubility and stability. Hydroxypropyl-beta-cyclodextrin (HPβCD) is used as a pharmaceutical excipient to facilitate the formulation and delivery of drugs that would otherwise have limited aqueous solubility. In the context of Cyclo Therapeutics' development, HPβCD is being investigated as a therapeutic agent itself for certain lysosomal storage disorders where it may help mobilize and clear accumulated lipids.","oneSentence":"Hydroxypropyl-beta-cyclodextrin is a solubilizing excipient that forms inclusion complexes with lipophilic drugs to improve their bioavailability and enable intravenous delivery.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:20.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Niemann-Pick disease type C (NPC)"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT03471143","phase":"PHASE1, PHASE2","title":"Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-02-22","conditions":"Niemann-Pick Disease, Type C","enrollment":4},{"nctId":"NCT06679322","phase":"PHASE2","title":"The Androtriol Injection for the Treatment of Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-10-31","conditions":"Acute Ischemic Stroke","enrollment":300},{"nctId":"NCT05033444","phase":"PHASE1","title":"A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers","status":"COMPLETED","sponsor":"Odyssey Group International, Inc.","startDate":"2022-02-09","conditions":"Traumatic Brain Injury (TBI)","enrollment":40},{"nctId":"NCT04860960","phase":"PHASE3","title":"Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cyclo Therapeutics, Inc.","startDate":"2021-07-20","conditions":"Niemann-Pick Disease, Type C1","enrollment":94},{"nctId":"NCT03643562","phase":"PHASE3","title":"Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System","status":"TERMINATED","sponsor":"Mandos LLC","startDate":"2018-06-18","conditions":"Niemann-Pick Type C Disease","enrollment":27},{"nctId":"NCT03879655","phase":"PHASE2, PHASE3","title":"Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1","status":"TERMINATED","sponsor":"Mandos LLC","startDate":"2019-12-02","conditions":"Niemann-Pick Disease, Type C","enrollment":2},{"nctId":"NCT04958642","phase":"PHASE2, PHASE3","title":"Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease","status":"TERMINATED","sponsor":"Mandos LLC","startDate":"2015-12-23","conditions":"Niemann-Pick Disease, Type C","enrollment":66},{"nctId":"NCT05607615","phase":"PHASE2","title":"A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease","status":"UNKNOWN","sponsor":"Cyclo Therapeutics, Inc.","startDate":"2022-09-23","conditions":"Alzheimer's Disease","enrollment":90},{"nctId":"NCT02534844","phase":"PHASE2, PHASE3","title":"VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease","status":"COMPLETED","sponsor":"Mandos LLC","startDate":"2015-10","conditions":"Niemann-Pick Disease, Type C","enrollment":56},{"nctId":"NCT02912793","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients","status":"COMPLETED","sponsor":"Cyclo Therapeutics, Inc.","startDate":"2017-03-20","conditions":"Niemann-Pick Disease, Type C1","enrollment":12},{"nctId":"NCT01747135","phase":"PHASE1","title":"Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease","status":"COMPLETED","sponsor":"Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company","startDate":"2013-01","conditions":"Niemann-Pick Disease, Type C1","enrollment":14},{"nctId":"NCT02939547","phase":"PHASE1","title":"Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)","status":"COMPLETED","sponsor":"Cyclo Therapeutics, Inc.","startDate":"2017-10-11","conditions":"Niemann-Pick Disease, Type C1","enrollment":13},{"nctId":"NCT02418676","phase":"PHASE1, PHASE2","title":"Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers","status":"COMPLETED","sponsor":"State University of Maringá","startDate":"2013-03","conditions":"Pressure Ulcer, Wound","enrollment":15},{"nctId":"NCT02224079","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-04","conditions":"Healthy","enrollment":100},{"nctId":"NCT00914745","phase":"PHASE2","title":"Place Controlled Study to Treat Recurrent Herpes Labialis.","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2009-04","conditions":"Recurrent Herpes Labialis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3234,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hydroxypropyl-beta-cyclodextrin (HP-β-CD)","Trappsol Cyclo"],"phase":"phase_3","status":"active","brandName":"Hydroxypropyl-beta-cyclodextrin","genericName":"Hydroxypropyl-beta-cyclodextrin","companyName":"Cyclo Therapeutics, Inc.","companyId":"cyclo-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxypropyl-beta-cyclodextrin is a solubilizing excipient that forms inclusion complexes with lipophilic drugs to improve their bioavailability and enable intravenous delivery. Used for Niemann-Pick disease type C (NPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}